.svg) | |
.svg) | |
| Combination of | |
|---|---|
| Cabotegravir | Integrase strand transfer inhibitor (INSTI) |
| Rilpivirine | Non-nucleoside reverse transcriptase inhibitor (NNRTI) |
| Clinical data | |
| Trade names | Cabenuva |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a621009 |
| License data | |
| Pregnancy category |
|
| Routes of administration | Intramuscular |
| Legal status | |
| Legal status | |
Cabotegravir/rilpivirine, sold under the brand name Cabenuva, is a co-packaged medication used to treat HIV/AIDS.[3] In those who are at least 12 years old, it is generally all the medications needed to treat the disease.[3] It is given by injection into a muscle.[3] It is packaged with two separate vials.[3]
Common side effects include injection site reactions, fever, tiredness, headache, musculoskeletal pain, nausea, sleep disorders, dizziness, and rash.[3] Other side effects may include allergic reactions, liver problems, and depression.[3] It contains cabotegravir, an HIV-1 integrase strand transfer inhibitor (INSTI), and rilpivirine, an HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI).[3]
The combination was approved for medical use in Canada and Europe in 2020 and the United States in 2021.[4][3][1] In Europe, the two medications are approved separately.[5][6] In the United States it costs about 4,400 USD per month as of 2022.[7]
References edit
- ^ a b "Cabenuva Product information". Health Canada. 25 April 2012. Archived from the original on 14 May 2021. Retrieved 22 January 2021.
- ^ "Summary Basis of Decision (SBD) for Vocabria/Cabenuva". Health Canada. 23 October 2014. Archived from the original on 30 May 2022. Retrieved 29 May 2022.
- ^ a b c d e f g h i j k "Cabenuva- cabotegravir and rilpivirine kit". DailyMed. Archived from the original on 15 June 2021. Retrieved 13 February 2021.
- ^ "Janssen Announces European Commission Authorisation of the First Complete Long-Acting Injectable HIV Treatment in Europe" (Press release). Janssen. Archived from the original on 12 November 2021. Retrieved 22 January 2021 – via Business Wire.
- ^ "Rekambys EPAR". European Medicines Agency (EMA). 13 October 2020. Archived from the original on 8 January 2021. Retrieved 4 January 2021.
- ^ "Vocabria EPAR". European Medicines Agency (EMA). 5 January 2021. Archived from the original on 14 July 2021. Retrieved 5 January 2021.
- ^ "Cabenuva Prices, Coupons, Copay & Patient Assistance". Drugs.com. Archived from the original on 22 April 2021. Retrieved 1 November 2022.